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severely impaired muscle mass in newly diagnosed CD chil-
dren. Bone metabolism and muscle mass improved within 
3  months after starting EEN with no further normalization 
thereafter.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 In children with Crohn’s disease (CD), exclusive en-
teral nutrition (EEN) therapy is as effective as systemic 
corticosteroids in inducing remission  [1, 2] and even su-
perior in terms of mucosal healing, side effects, correction 
of malnutrition, and patients’ general well-being  [3–6] . 
Furthermore, EEN may have additional benefits on bone 
health. Reduced bone density and increased fracture risk 
are well-known sequelae in CD patients  [7] . Particularly, 
growing children and adolescents with CD are prone to 
disturbed bone metabolism. We and others have de-
scribed low trabecular and high cortical density and al-
terations in bone geometry earlier in pediatric CD co-
horts  [8–10] . The combination of malnutrition, excessive 
inflammatory mediators, corticosteroid use, and reduced 
physical activity are the most important factors for im-
paired bone and muscle development during growth and 
may increase the risk for osteoporosis later in life  [7, 10] . 
EEN may help to reduce most of the detrimental effects 
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 Abstract 
 Background and Aims: Exclusive enteral nutrition (EEN) in-
duces remission in patients with Crohn’s disease (CD). We 
investigated the short-term impact of EEN on bone quality 
and muscle mass in children with CD.  Methods: Ten newly 
diagnosed CD patients (7 male, 10.6–17.7 years of age) were 
assessed by peripheral quantitative computed tomography 
(pQCT) at the forearm before starting an 8-weeks treatment 
with EEN, and after 12 and 52 weeks. No steroids or biologi-
cals were applied. Trabecular and cortical bone mineral den-
sity, total bone, and muscle cross-sectional area (CSA) were 
measured by pQCT and expressed as age- and sex-specific 
z-scores; size-dependent CSAs were corrected for low height 
for age. Wilcoxon rank sum test was applied.  Results: Remis-
sion at week 12 was achieved in 8 patients; 2 still had mild 
disease. Initially low trabecular density z-scores improved 
(+0.3; p = 0.006) at week 12; simultaneously, the increased 
cortical density z-scores normalized (–0.4; p = 0.027). The low 
z-score for muscle CSA corrected for height (median –2.5, 
range –3.49 to –0.97) increased within 12 weeks (+1.0; p = 
0.002) with no further improvement thereafter.  Conclu-
sions: The results indicate disturbed bone remodeling and 
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of CD on bone health in pediatric patients. However, only 
few data are available, which are all of a retrospective na-
ture or investigating bone markers only  [11, 12] .
 The aim of this study was to investigate the short-term 
impact of nutritional therapy on bone mineral density, 
geometry, and muscle mass measured by peripheral 
quantitative computed tomography (pQCT) within 
1  year after diagnosis and initial EEN treatment. Since 
bone strength depends not only on bone mineral content 
and bone density but also on bone geometry, pQCT is an 
excellent tool to locally assess true volumetric density, to 
distinguish between trabecular and cortical bone, and to 
assess total bone and muscle cross-sectional areas (CSAs) 
 [13] . In addition, we monitored short-term effects of EEN 
on bone metabolism by several biomarkers.
 Materials and Methods 
 Patients with newly diagnosed, active CD were recruited con-
secutively if they were between 6 and 18 years old. All patients were 
diagnosed according to ESPGHAN (European Society of Pediat-
ric Gastroenterology, Hepatology and Nutrition) criteria  [14] and 
started on EEN therapy after informed consent was signed. Exclu-
sion criteria for recruitment were small bowel resection (>100 cm), 
ileostomy, other extra-intestinal organic or systemic diseases 
which may affect the nutritional status and/or bone metabolism, 
prior therapy with calcitonin, bisphosphonates, growth hormone 
or anabolic steroids, or current or recent participation in another 
clinical trial. If treatment with steroids or biologicals (e.g. inflix-
imab) or surgery was indicated during the study, the patient was 
excluded from further analysis.
 At diagnosis and at each follow-up visit at 4, 12, 24, and 
52 weeks after the baseline visit, the recent medical history was re-
corded using a standardized questionnaire; physical examination, 
anthropometric measures, and grip strength were performed; 
pQCT was measured at diagnosis and at follow-up visits at week 12 
and 52. To assess the disease activity, we calculated the Pediatric 
Crohn’s Disease Activity Index (PCDAI)  [15] . Scores <10 were 
considered as remission, between 10 and 27.5 as mild, between 30 
and 37.5 as moderate, and >37.5 as severe disease activity.
 For the EEN therapy, a liquid casein-based polymeric formula 
(Modulen ® ; Nestlé, Frankfurt, Germany) was consumed orally or 
by nasogastric tube feeding for 8 weeks. During this period, only 
water and chewing gum was allowed. Formula volume was based 
on the estimated energy requirements for ideal weight for height. 
EEN was followed by a 2- to 4-week stepwise transition to normal 
diet, starting with low allergenic food, while formula volume was 
gradually decreased. Ongoing supplementation with enteral nutri-
tion formula was not performed.
 Anthropometry, Pubertal Stage, Bone Age, and Grip Force 
 Height was measured in a standing position to the nearest 1 mm 
with a digital telescopic wall-mounted stadiometer (Ulmer Stadi-
ometer; Prof. E. Heinze, Ulm, Germany). Weight was determined 
to the nearest 0.1 kg using an electronic scale (Seca 753 E; Vogel and 
Hanke, Hamburg, Germany), while the patients were undressed 
except for underwear. Body mass index (BMI) was calculated as 
weight (kg)/[height (m)] 2 . Height, weight, and BMI were compared 
with the longitudinal growth data of the German growth study  [16] .
 The pubertal stage was assessed by the grading system of Tan-
ner  [17] (according to breast development in girls and testicular 
volume in boys) and grouped as follows: Tanner 1 (prepubertal), 
Tanner 2 and 3 (early pubertal), and Tanner 4 and 5 (adolescent).
 Bone age was determined at diagnosis and week 52 by radiog-
raphy of the left hand according to the method of Greulich and 
Pyle  [18] to assess whether a comparison with the age-matched 
reference data was eligible. Patients were asked for previous bone 
fractures.
 Maximal isometric grip force of the non-dominant hand was 
determined by an adjustable-handle Jamar Dynamometer (Pres-
ton, Jackson, Mich., USA). Reference data for forearm length and 
grip force were taken from the German DONALD (Dortmund Nu-
tritional and Anthropometric Longitudinally Designed) study  [19] .
 Peripheral Quantitative Computed Tomography 
 Bone and muscle parameters were measured by pQCT (XCT-
2000 scanner; Stratec, Pforzheim, Germany) as described previ-
ously  [20] . In brief, at the nondominant forearm, the scanner was 
positioned corresponding to 4 and 65% of forearm length, and at 
both sites 2-mm-thick single tomographic slices were measured 
with a voxel size of 0.4  mm. Image processing and calculation of 
numerical values were performed by the manufacturer’s software 
package (v.5.50; Stratec). At the 4% site (distal radius, metaphysis) 
trabecular bone mineral density and at the 65% site (proximal ra-
dius, diaphysis) cortical bone mineral density, total bone, and 
muscle CSA were determined.
 The data were compared with reference data from 296 healthy 
German children and adolescents  [21, 22] . As growth retardation 
is common in children and adolescents with inflammatory bowel 
disease, the bone size-dependent parameters (total and muscle 
CSA) were corrected for height (CSA height ).
 Biomarkers of Inflammation and Bone Metabolism 
 At baseline, week 12, 24, and 52, the following markers of in-
flammation were analyzed: erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), and fecal calprotectin. Bone parameters 
were analyzed as described previously  [20] at baseline, week 4, 12, 
and 24 and included insulin-like growth factor 1 (IGF-1), insulin-
like growth factor-binding protein 3 (IGF-BP), C-terminal propep-
tide of type I collagen (C1CP), bone-specific alkaline phosphatase 
(bsaP), intact parathyroid hormone (iPTH), desoxypyridinoline 
(DPD, urine), and 25-OH vitamin D. A 25-OH vitamin D level 
<10 ng/ml was considered as insufficient, between 10 and 20 ng/ml 
as deficient, and >20 ng/ml as normal. In addition, vitamin K sta-
tus was assessed by measuring plasma phylloquinone (vitamin K1) 
and PIVKA-II (prothrombin produced in vitamin K absence)  [23] . 
Vitamin K1 was measured by high performance liquid chromatog-
raphy;  a suboptimal concentration was defined as  ≤ 0.15 ng/ml. 
PIVKA-II was analyzed by enzyme-linked immunosorbent assay. 
Values of  ≥ 0.3 AU/ml were considered as abnormally increased.
 Statistics and Ethics 
 Sex-, age-, and height-specific z-scores were calculated using 
the formula: z-score = [(test result for a patient) – (sex-, age-, or 
height-specific mean in reference population)]/(sex-, age-, or 
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height-specific standard deviation in reference population). To ex-
amine changes over time, individual differences in parameters be-
tween baseline and follow-up visits and differences between the 
follow-up visits were calculated. For all parameters and differenc-
es, median and range were given; Wilcoxon rank sum test was ap-
plied to test the differences and z-scores. Spearman correlation was 
applied to examine associations between changes in bone bio-
markers and changes in pQCT parameters. For all tests, a p value 
<0.05 was regarded as significant.
 The study protocol was approved by the Federal Office for Ra-
diation Protection (Salzgitter, Germany; approval Z5-22462/2-
2004-051) and the Ethical Committee of the Medical Faculty of the 
University of Munich (project 202/04). Written informed consent 
was obtained from all parents and patients.
 Results 
 Fifteen patients with newly diagnosed CD had been 
identified as eligible to participate. Two patients refused to 
participate in the study. Of the 13 included patients, 1 pa-
tient had to be excluded from the study at 4 weeks and 2 
patients at 12 weeks because they required treatment with 
biologicals due to worsening of perianal fistulizing disease.
 The basic characteristics of the 10 patients with com-
plete follow-up are summarized in  table 1 . Two patients 
showed mild (1 year) and 1 patient severe (2 years) retar-
dation in bone age at diagnosis. The median difference 
between bone age and chronological age was –0.3 years 
(range –2.2 to 0.6). None of the patients reported previ-
ous bone fractures.
 All 10 patients completed 8 weeks of EEN. In parallel, 
all patients started azathioprine therapy with a median 
time gap of 8 days (range 0 to 29 days) after induction of 
EEN; 9 patients started 5-aminosalicyl-acid (5-ASA) 
therapy with a median time gap of 5 days (range 0 to 
14 days) after EEN. During follow-up, all patients contin-
ued azathioprine and 5-ASA therapy. None of them re-
ceived steroids or biologicals between baseline and week 
52. Five patients received proton-pump inhibitors, and 1 
patient was treated with antibiotics at week 24.
 According to the PCDAI, most of the patients had 
mild to moderate disease activity at diagnosis ( table 2 ). 
Twelve weeks after initiation of therapy, 8 patients were 
in remission and 2 had mild disease (PCDAI 10 and 25). 
Between week 12 and 52, 7 of 10 patients relapsed; 4 of 
them repeated EEN between week 24 and 52.
 Bone biomarkers at diagnosis and differences between 
follow-ups are summarized in  table 3 . Significant increas-
es from baseline to week 4 or 12 were detected for iPTH, 
bsaP, C1CP, IGF-1, IGF-BP, and DPD (the latter only for 
baseline to week 4). No significant changes were seen be-
tween week 12 and 24. PIVKA-II was normal or below 
detection level for all patients at diagnosis and during fol-
low-up (data not shown).
 Z-scores for height and BMI were impaired at baseline 
but increased significantly for BMI  within the 12 weeks 
after initiation of EEN ( table 4 ). Height z-scores did not 
improve. Trabecular density z-scores seemed to be low, 
while cortical density z-scores tended to be increased at 
baseline, both without reaching statistical significance; 
total CSA height z-scores were on a normal level. Between 
baseline and week 12, trabecular density ( table 4 ,  fig. 1 , 
and online suppl. fig., www.karger.com/doi/10.1159/ 
000350369) and total CSA height z-scores significantly in-
creased, while initially high cortical-density z-scores de-
creased towards normal ( table 4 ,  fig. 1 , and online suppl. 
fig.). Both muscle CSA height and grip strength z-scores 
were markedly reduced at diagnosis and clearly improved 
after EEN had been completed ( table 4 ,  fig. 1 ).
 For all anthropometric and pQCT parameters, signifi-
cant changes in z-scores were only detected in the first 
12  weeks after initiation of EEN but not between later 
follow-up visits ( table 4 ); a similar observation was made 
regarding the changes in bone biomarkers ( table  3 ). 
When we correlated the changes of bone biomarkers 
(baseline to week 4) with changes in bone density z-scores 
(baseline to week 12), a trend towards a positive associa-
tion between C1CP and trabecular density (r = 0.65; p = 
0.057) or a trend towards a negative correlation between 
C1CP and cortical density (r = –0.61; p = 0.081) was seen. 
 Discussion 
 To our knowledge, this is the first study to assess short-
term effects of EEN not only on bone biomarkers but also 
on bone density and geometry in newly diagnosed pedi-
Table 1.  Baseline characteristics of patients (n = 10)
Variable
Male patients, n 7
Median age (range), years 13.7 (10.6; 17.7)
Median bone age (range), years 13.5 (8.5; 18.0)
Tanner staging, n
Prepubertal/early pubertal/adolescent 2/4/4
Disease localization, n
Ileocolonic/colonic
Upper gastrointestinal tract involved
Perianal fistula
9/1
6
0
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atric CD patients. Unexpectedly, we observed significant 
changes towards normalization only within 3 months af-
ter initial diagnosis and treatment with EEN. Our data 
support the hypothesis that EEN positively affects bone 
and muscle parameters in newly diagnosed pediatric CD 
patients.
 As previously described, low trabecular plus high corti-
cal density indicate disturbed bone turnover, which is fre-
quent in children and adolescents with CD  [8, 9] . In the 
present cohort, trabecular bone mineral density increased, 
while high cortical density normalized, most likely due to 
enhanced remodeling in the cortical bone and formation 
Table 2.  PCDAI, CRP, ESR, and calprotectin as parameters of disease activity at baseline and follow-up visits
Baseline 12 weeks 24 weeks 52 weeks
PCDAI 
Remission/mild/moderate/severe activity, n 0/3/5/2 8/1/1/0 5/4/0/1 7/2/0/1
Median CRP (range), mg/dl 
>0.5 mg/dl, n/total 
2.3 (0.3; 5.0)
8/10
0.3 (0.1; 3.1)
7/10
0.1 (0.6; 7.0)
5/10
0.2 (0.1; 3.7)
3/10
Median ESR (range), mm/h
>15 mm/h, n/total 
46 (11; 79)
8/10
28 (6; 51)
7/10
24 (13; 68)
7/10
24 (10; 53)
7/10
Median calprotectin (range), mg/g
>50 mg/g feces, n/total 
503 (114; 3,475)
10/10
521 (0; 1,110)
8/10
419 (0; 1,483)
9/10
373 (0; 1,548)
6/9
Values are number of patients for PCDAI, and median (range) and proportion of patients above the normal limit for CRP, ESR, and 
calprotectin.
Table 3.  Bone biomarkers at baseline
Baseline Differences
baseline to week 4
Differences
baseline to week 12
Differences
week 12–24
Vitamin K1, ng/ml
≤0.15 ng/ml
0.17 (0.05; 2.68)
5/10
0.41 (–2.32; 0.73)
p = 0.250
0.0 (–2.59; 0.56)
p = 0.461
Not done
25-OH vitamin D, ng/ml
<20 ng/ml 
24.8 (10.6; 32.0)
3/10 
2.5 (–7.9; 13.8)b
p = 0.426
3.1 (–12.0; 19.2)
p = 0.061
0.65 (–25.5; 15.5)c
p = 0.945
iPTH, pg/ml
>normal limita
23.0 (17.1; 45.4)
1/10
7.4 (1.5; 15.6)
p = 0.002
15.0 (–8.7; 34.9)b
p = 0.016
4.8 (–8.7; 26.9)b
p = 0.250
bsaP, U/l
<normal limita
47 (31; 74)
0/10
24 (–5; 123)b
p = 0.012
34 (12; 113)b
p = 0.004
–20 (–85; 39)b
p = 0.193
C1CP, ng/ml
<normal limita
83.5 (48; 236) 
6/10
156 (56; 362)b
p = 0.004
113 (31; 530)b
p = 0.004
–53 (–114; 166)b
p = 0.641
IGF-1, ng/ml
<normal limita
112 (41; 283) 
7/10
158 (–39; 272)b
p = 0.008
161 (13; 255)b
p = 0.004
–2 (–76; 99)b
p = 0.910
IGF-BP, μg/ml
<normal limita
3.3 (0.8; 4.3)
1/10
1.7 (–0.1; 3.0)b
p = 0.008
0.9 (–0.3; 2.1)b
p = 0.012
0.0 (–0.7; 1.4)b
p = 0.867
DPD, μg/g Creatinin
>normal limita
202 (115; 467)b
0/10
64.5 (–28; 637)c
p = 0.039
36 (–75; 165)c
p = 0.219
–30.5 (–146; 46)c
p = 0.078
 Values are median (range) and proportion of patients with abnormal values compared to age- and sex-specific normal values; dif-
ferences between follow-up analysis: median (range) and p value. a Related to age- and sex-specific normal values. b Number of patients: 
9. c Number of patients: 8.
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of new Haversian canals. Reduced muscle CSA and grip 
strength clearly improved during initial nutritional thera-
py but not afterwards. In parallel, C1CP and bsaP as bio-
markers of bone formation increased significantly; DPD 
as a parameter of bone resorption also increased, probably 
due to overall improved bone remodeling, which requires 
not only bone formation, but also resorption during 
growth and skeletal development  [24] . Similar effects of 
EEN on normalization of bone biomarkers had already 
been reported in Australian pediatric CD patients  [11] .
 Several potential mechanisms of EEN on bone metab-
olism had been postulated. A rapid decrease of proin-
flammatory markers and cytokines, such as CRP, ESR, 
and IL-6, within the first week of EEN had been shown 
earlier in pediatric CD patients  [25] . Decrease of inflam-
mation most likely led to normalization of bone modeling 
in our patients, resulting in increased bone formation in 
the trabecular bone and normalization of low level of 
bone remodeling in the cortical bone. Two studies in 
adult and pediatric CD patients had shown similar short-
term effects on bone biomarkers after induction of remis-
sion with infliximab  [24, 26] . However, both studies did 
not apply pQCT to investigate the changes in the different 
bone compartments and the muscle mass.
 Correction of malnutrition is another potential factor 
for improving bone health by EEN. CD patients frequent-
ly present with protein-energy malnutrition at diagnosis 
and deficiency of micronutrients  [27] . EEN may have di-
rect effects on bone metabolism by providing important 
micronutrients such as calcium, which is the main bone 
mineral, and vitamin D, which regulates serum calcium 
levels; vitamin K is important for carboxylation of osteo-
calcin, the major noncollagenous protein in bones  [28] . 
However, in our cohort, no association between changes 
in vitamin D and K levels and bone parameters were ob-
served. More likely, EEN influences bone accrual indi-
rectly by correction of protein-energy malnutrition. We 
consider that the high increase in IGF-1 and C1CP during 
EEN reflects improved nutritional status, and both pa-
rameters are positively associated with bone modeling. 
Secondly, the gain in muscle mass is at least in part a con-
sequence of improved protein-energy supply. The con-
cept of a muscle-bone unit suggests that muscle strength 
strongly modulates bone strength  [29] . This strong asso-
ciation was confirmed in our prospective long-term study 
and applies to pediatric inflammatory bowel disease pa-
tients both with CD and ulcerative colitis  [9] . In addition, 
improvements in muscle mass and increased general 
well-being may have increased the physical activity of our 
patients after starting on EEN and this may also have con-
tributed to the changes in bone density and structure.
Table 4.  Z-scores for height, BMI, trabecular and cortical density, total and muscle CSAheight, and grip strength at baseline compared to 
reference population and differences between measurements
Baseline z-scores compared to reference z-score differences baseline to week 12  z-score differences week 12–52
median (range) p value median (range) p value medi an (range) p value
Height –1.07 (–2.25; 0.29) 0.027 –0.01 (–0.14; 0.47) 0.625 0.05 (–0.26; 1.07) 0.748
BMI –1.25 (–2.02; 0.18) 0.004 0.53 (–0.29; 0.92) 0.006 0.05 (–1.56; 1.35) 0.625
Trabecular density –0.78 (–1.96; 1.37) 0.193 0.30 (–0.03; 0.99) 0.006 0.35 (–1.81; 1.19) 0.432
Cortical density 0.91 (–0.42; 2.24) 0.065 –0.40 (–1.07; 0.49) 0.027 –0.08 (–0.92; 1.27) 0.625
Total CSAheight 0.13 (–0.90; 0.87) 0.910 0.23 (–0.19; 0.55) 0.014 0.32 (–0.23; 4.25) 0.037
Muscle CSAheight –2.53 (–3.49; –0.97) 0.002 0.99 (0.59; 1.75) 0.002 –0.11 (–0.67; 0.83) 0.375
Grip strength –1.73 (–2.84; 0.82) 0.020 0.74 (–0.99; 2.80) 0.065 0.36 (–1.55; 2.71) 0.492
1.5
Cortical density
Trabecular density
Muscle CSA
1.0
0.5
0
–0.5
–1.0
–1.5
–2.0
–2.5
–3.0
0 12
Time (weeks)
z-
sc
or
e
52
 Fig. 1.  Development of z-score medians for trabecular and cortical 
density, and muscle CSA height . 
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 The impact of corticosteroid therapy on bone health in 
CD patients is still controversially discussed  [7] . Short-
term therapy with corticosteroids does not appear to neg-
atively affect bone mineral density  [9] . A British study in 
95 adult women with CD showed that patients who were 
treated predominantly with nutritional therapy or only 
small lifetime doses of steroids (<5 g) or no steroids at all 
did not differ from controls in their bone density. In con-
trast, patients with a lifetime dose of >5 g prednisolone 
had a significantly lower bone mineral density than age- 
and gender-matched controls  [12] .
 Our study has several strengths and limitations. An ad-
vantage is that the study group was relatively homoge-
nous, including only newly diagnosed patients without 
fistulizing disease. The major advantage was the use of 
pQCT instead of commonly applied dual energy X-ray ab-
sorptiometry, which has the drawbacks that it measures 
bone mass (g/cm 2 ) only, is subject to growth-related arti-
facts, and systemically underestimates the bone density of 
stunted individuals  [13] . As the radiation dose is extreme-
ly low with 0.6 μSv, pQCT is highly suitable for a longitu-
dinal investigation in children and adolescents. The close 
follow-up of our patients already 12 weeks after initiation 
of EEN is another important strength of our study which 
enabled us to detect the positive short-term effects of EEN 
on bone structure. In addition, pQCT measurements were 
supported by the changes in bone biomarkers.
 The major limitations are the small sample size and the 
lack of a control group of CD patients treated with corti-
costeroids or infliximab for induction of remission. There-
fore, it remains unclear whether EEN is superior, for ex-
ample, compared to infliximab in terms of better improve-
ment of bone parameters due to potential nutritional 
effects. However, due to ethical considerations it was not 
possible to have such a control group since EEN is already 
well established as a first-line therapy in Europe  [14] . 
Therefore, the strength of our results is limited and we can 
only speculate on the mechanisms responsible for the pos-
itive effect of EEN on bone health. All patients started on 
azathioprine during EEN. However, this drug develops its 
main efficacy only after 2–4 months. The follow-up at 3 
months showed the greatest improvement in bone model-
ing and biomarkers, while there was no further improve-
ment thereafter in spite of continued azathioprine therapy.
 In conclusion, low trabecular and high cortical bone 
density at diagnosis indicate disturbed bone remodeling. 
Muscle CSA, corrected for low height for age, as well as 
grip strength were significantly impaired. Within only 
3 months after initiation of EEN therapy, bone metabo-
lism and muscle mass significantly improved towards 
normalization, most likely due to reduced inflammation 
in combination with nutritional support. Further investi-
gations are needed to evaluate the impact and mecha-
nisms of EEN on bone and muscle development in newly 
diagnosed pediatric CD patients, preferably in compari-
son to a control group treated with steroids or biologicals. 
In addition, the effect of partial enteral nutrition (for ex-
ample, nighttime feeding, with a normal diet during the 
day) to further improve bone health and muscle mass in 
pediatric CD patients should be evaluated.
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